{"title":"微创骶尾部成形术后的持续性和新发压力性尿失禁。","authors":"Annika Sinha, Meng Yao, Cecile A Ferrando","doi":"10.1097/SPV.0000000000001454","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Data on stress urinary incontinence (SUI) after minimally invasive sacrocolpopexy (SCP) with or without midurethral sling placement are limited.</p><p><strong>Objective: </strong>The aim of the study was to determine the incidence of SUI after minimally invasive sacrocolpopexy.</p><p><strong>Study design: </strong>This was a secondary analysis of 2 randomized clinical trials of participants undergoing SCP. Participants completed symptom assessment and urodynamic testing. Participants underwent SCP with or without midurethral sling placement. Preoperatively, participants were defined as having symptomatic SUI, occult SUI, or no SUI. Participants completed the Pelvic Floor Distress Inventory-20 at 6 and 12 months postoperatively and were categorized as having persistent SUI in the setting of symptomatic or occult SUI or de novo SUI.</p><p><strong>Results: </strong>Eighty-one participants were included. Sixty-one participants met inclusion criteria for the persistent SUI analysis: 42 participants with symptomatic SUI and 19 participants with occult SUI. There were 20 participants in the de novo SUI group. The overall incidence of persistent SUI was 26.2% (95% confidence interval [CI], 15.8%-39.1%) with 33.3% (95% CI, 19.6%-49.6%) of symptomatic and 10.5% (95% CI, 1.5%-33.1%) of occult participants. Bothersome symptoms were defined as \"moderately\" or \"quite a bit\" bothered postoperatively. Of participants with symptomatic SUI, 14.3% participants were bothered and no participants underwent retreatment. No patient with occult SUI was bothered; however, 1 patient underwent retreatment. The incidence of de novo SUI was 45% (95% CI, 23.1%-68.5%). No patient in the de novo SUI group was bothered or underwent SUI treatment.</p><p><strong>Conclusions: </strong>Approximately 1 in 4 participants reported persistent SUI. Almost 50% reported de novo SUI. However, few participants were bothered or underwent treatment.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persistent and De Novo Stress Urinary Incontinence After Minimally Invasive Sacrocolpopexy.\",\"authors\":\"Annika Sinha, Meng Yao, Cecile A Ferrando\",\"doi\":\"10.1097/SPV.0000000000001454\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Data on stress urinary incontinence (SUI) after minimally invasive sacrocolpopexy (SCP) with or without midurethral sling placement are limited.</p><p><strong>Objective: </strong>The aim of the study was to determine the incidence of SUI after minimally invasive sacrocolpopexy.</p><p><strong>Study design: </strong>This was a secondary analysis of 2 randomized clinical trials of participants undergoing SCP. Participants completed symptom assessment and urodynamic testing. Participants underwent SCP with or without midurethral sling placement. Preoperatively, participants were defined as having symptomatic SUI, occult SUI, or no SUI. Participants completed the Pelvic Floor Distress Inventory-20 at 6 and 12 months postoperatively and were categorized as having persistent SUI in the setting of symptomatic or occult SUI or de novo SUI.</p><p><strong>Results: </strong>Eighty-one participants were included. Sixty-one participants met inclusion criteria for the persistent SUI analysis: 42 participants with symptomatic SUI and 19 participants with occult SUI. There were 20 participants in the de novo SUI group. The overall incidence of persistent SUI was 26.2% (95% confidence interval [CI], 15.8%-39.1%) with 33.3% (95% CI, 19.6%-49.6%) of symptomatic and 10.5% (95% CI, 1.5%-33.1%) of occult participants. Bothersome symptoms were defined as \\\"moderately\\\" or \\\"quite a bit\\\" bothered postoperatively. Of participants with symptomatic SUI, 14.3% participants were bothered and no participants underwent retreatment. No patient with occult SUI was bothered; however, 1 patient underwent retreatment. The incidence of de novo SUI was 45% (95% CI, 23.1%-68.5%). No patient in the de novo SUI group was bothered or underwent SUI treatment.</p><p><strong>Conclusions: </strong>Approximately 1 in 4 participants reported persistent SUI. Almost 50% reported de novo SUI. However, few participants were bothered or underwent treatment.</p>\",\"PeriodicalId\":75288,\"journal\":{\"name\":\"Urogynecology (Hagerstown, Md.)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urogynecology (Hagerstown, Md.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/SPV.0000000000001454\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urogynecology (Hagerstown, Md.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/SPV.0000000000001454","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
重要性:有关微创骶尾部整形术(SCP)后压力性尿失禁(SUI)的数据有限,无论是否放置尿道中段吊带:研究旨在确定微创骶尾部结扎术后 SUI 的发生率:研究设计:这是对两项随机临床试验参与者进行的二次分析。参与者完成了症状评估和尿动力学测试。参试者在接受骶尾部结肠切除术的同时接受或不接受尿道中段吊带置入术。术前,参与者被定义为有症状的 SUI、隐匿性 SUI 或无 SUI。参试者在术后 6 个月和 12 个月完成盆底压力量表-20,并被分为有症状或隐匿性 SUI 的持续性 SUI 或新发 SUI:结果:共纳入 81 名参与者。有 61 名参与者符合持续性 SUI 分析的纳入标准:42 名参与者有症状性 SUI,19 名参与者有隐匿性 SUI。新发 SUI 组有 20 人。持续性 SUI 的总发生率为 26.2%(95% 置信区间 [CI],15.8%-39.1%),其中有症状的参与者占 33.3%(95% CI,19.6%-49.6%),隐匿性参与者占 10.5%(95% CI,1.5%-33.1%)。令人烦恼的症状被定义为术后 "中度 "或 "相当 "令人烦恼。在有症状的 SUI 患者中,14.3% 的患者感到困扰,没有患者接受再治疗。没有隐匿性 SUI 患者受到困扰,但有一名患者接受了再治疗。新发 SUI 的发生率为 45%(95% CI,23.1%-68.5%)。新发 SUI 组中没有患者受到困扰或接受 SUI 治疗:结论:约四分之一的参与者报告了持续性 SUI。结论:每 4 名参与者中约有 1 人报告有持续性 SUI,近 50% 报告有新 SUI。结论:大约每 4 名参与者中就有 1 人报告有持续性 SUI,近 50%的参与者报告有新 SUI,但很少有人感到困扰或接受治疗。
Persistent and De Novo Stress Urinary Incontinence After Minimally Invasive Sacrocolpopexy.
Importance: Data on stress urinary incontinence (SUI) after minimally invasive sacrocolpopexy (SCP) with or without midurethral sling placement are limited.
Objective: The aim of the study was to determine the incidence of SUI after minimally invasive sacrocolpopexy.
Study design: This was a secondary analysis of 2 randomized clinical trials of participants undergoing SCP. Participants completed symptom assessment and urodynamic testing. Participants underwent SCP with or without midurethral sling placement. Preoperatively, participants were defined as having symptomatic SUI, occult SUI, or no SUI. Participants completed the Pelvic Floor Distress Inventory-20 at 6 and 12 months postoperatively and were categorized as having persistent SUI in the setting of symptomatic or occult SUI or de novo SUI.
Results: Eighty-one participants were included. Sixty-one participants met inclusion criteria for the persistent SUI analysis: 42 participants with symptomatic SUI and 19 participants with occult SUI. There were 20 participants in the de novo SUI group. The overall incidence of persistent SUI was 26.2% (95% confidence interval [CI], 15.8%-39.1%) with 33.3% (95% CI, 19.6%-49.6%) of symptomatic and 10.5% (95% CI, 1.5%-33.1%) of occult participants. Bothersome symptoms were defined as "moderately" or "quite a bit" bothered postoperatively. Of participants with symptomatic SUI, 14.3% participants were bothered and no participants underwent retreatment. No patient with occult SUI was bothered; however, 1 patient underwent retreatment. The incidence of de novo SUI was 45% (95% CI, 23.1%-68.5%). No patient in the de novo SUI group was bothered or underwent SUI treatment.
Conclusions: Approximately 1 in 4 participants reported persistent SUI. Almost 50% reported de novo SUI. However, few participants were bothered or underwent treatment.